The clinical trials listed below are all open as of July 12, 2024; have ≥ 1 US Department of Veterans Affairs (VA) medical center (VAMC) or US Department of Defense (DoD) military treatment facility location recruiting patients; and are focused on treatments for prostate cancer. For additional information and full inclusion/exclusion criteria, please consult clinicaltrials.gov.
Actively Recruiting
Patient Decision Making About Precision Oncology in Veterans With Advanced Prostate Cancer
This clinical trial explores and implements methods to improve informed decision making regarding precision oncology tests among veterans with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Precision oncology, the use of germline genetic testing and tumor-based molecular assays to inform cancer care, has become an important aspect of evidence-based care for men with advanced prostate cancer. Veterans with metastatic castrate-resistant prostate cancer may not be carrying out informed decision making due to unmet decisional needs. An informed decision is a choice based on complete and accurate information. The information gained from this study will help researchers develop a decision support intervention and implement the intervention. A decision support intervention may serve as a valuable tool to reduce ongoing racial disparities in genetic testing and encourage enrollment to precision oncology trials.
ID: NCT05396872
Sponsor; Collaborator: University of California, San Francisco; DoD
Location: San Francisco VAMC
DeADT - Living Well With Prostate Cancer
The goal of this pilot randomized implementation trial is to compare 2 strategies to reduce low-value androgen deprivation therapy (ADT) use for prostate cancer care. The aim of the study is to compare implementation of the 2 strategies: use of a clinical reminder order check intervention vs a clinician script/patient education approach, and their impacts on low-value ADT use after 6 months. The main goal of both interventions will be to decrease ADT overuse for patients with prostate cancer, but to do this in a way that is acceptable to the provider who treat these patients. Provider participants will engage with 1 of the interventions triggered in the electronic health record when their patients are deemed likely to receive low-value ADT. Provider participants receive only 1 intervention. The intervention is triggered for every clinic visit involving a patient deemed to be receiving low-value ADT, so provider participants may receive their assigned intervention multiple times. Researchers will compare provider use of both strategies to determine implementation outcomes and whether 1 was more effective in reducing low-value ADT use.
ID: NCT06199986
Sponsor; Collaborator: University of Michigan; VA, National Cancer Institute
Location: VA Ann Arbor Healthcare System
VA Seamless Phase II/III Randomized Trial of Standard Systemic Therapy With or Without PET-Directed Local Therapy for Oligometastatic Prostate Cancer (VA STARPORT)
This is a prospective, open-label, multicenter, seamless phase II to phase III randomized clinical trial designed to compare somatostatin with or without positron emission tomography (PET)-directed local therapy in improving the castration-resistant prostate cancer-free survival for veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1 to 10 sites of metastatic disease based on the clinical determination.
ID: NCT04787744
Sponsor; Investigators: VA Office of Research and Development; Abhishek Solani, MD, MS, Edward Hines Jr.
Locations: VA Long Beach Healthcare System, VA Greater Los Angeles Healthcare System, Bay Pines VA Healthcare System, Edward Hines Jr. VA Hospital, Richard L. Roudebush VAMC, Baltimore VAMC, VA Boston Healthcare System, VA Ann Arbor Healthcare System, Minneapolis VA Health Care System, Kansas City VAMC, VA New Jersey Healthcare System, VA NY Harbor Healthcare System, Durham VAMC, Louis Stokes VAMC, Corporal Michael J. Crescenz VAMC, Michael E. DeBakey VAMC, Hunter Holmes McGuire VAMC, William S. Middleton Memorial Veterans Hospital, Clement J. Zablocki VAMC